Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Felbamate

B F Bourgeois1

  • 1Washington University School of Medicine, Epilepsy Center, St. Louis, MO 63110, USA.

Seminars in Pediatric Neurology
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

Felbamate, an antiepileptic drug, underwent unique clinical trials and was the first new drug in 15 years. Despite initial success, severe toxicity led to near market withdrawal, with current use limited to specific pediatric epilepsy cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Language lateralization represented by spatiotemporal mapping of magnetoencephalography.

AJNR. American journal of neuroradiology·2012
Same author

Rufinamide for the treatment of epileptic spasms.

Epilepsy & behavior : E&B·2011
Same author

Higher evening antiepileptic drug dose for nocturnal and early-morning seizures.

Epilepsy & behavior : E&B·2011
Same author

Magnetoencephalographic mapping of interictal spike propagation: a technical and clinical report.

AJNR. American journal of neuroradiology·2007
Same author

The value of multichannel MEG and EEG in the presurgical evaluation of 70 epilepsy patients.

Epilepsy research·2006
Same author

Pharmacokinetics and metabolism of topiramate.

Drugs of today (Barcelona, Spain : 1998)·2003
Same journal

Concussion in contact sport: risks, detection, & prevention.

Seminars in pediatric neurology·2026
Same journal

A multidisciplinary, symptom-targeted approach to rehabilitation in pediatric concussion.

Seminars in pediatric neurology·2026
Same journal

Pediatric concussion beyond sports: Falls, play, and everyday activities.

Seminars in pediatric neurology·2026
Same journal

Return-to-school protocols in pediatric concussion care.

Seminars in pediatric neurology·2026
Same journal

Improving concussion recognition in youth sports: the role of parents, coaches, and community education.

Seminars in pediatric neurology·2026
Same journal

Concussion management, rehabilitation, and societal impact.

Seminars in pediatric neurology·2026
See all related articles

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Felbamate's introduction marked a significant event in epilepsy treatment.
  • Its development involved novel clinical trial designs previously unused for antiepileptic drugs.

Purpose of the Study:

  • To highlight the unique clinical trial methodologies employed for felbamate.
  • To discuss the drug's market trajectory, including its near withdrawal due to safety concerns.

Main Methods:

  • Pioneering double-blind trials in patients withdrawn from other antiepileptic drugs (AEDs).
  • First double-blind monotherapy trials for an AED.
  • First placebo-controlled trial in pediatric Lennox-Gastaut syndrome.

Main Results:

Related Experiment Videos

  • Felbamate was the first new AED in 15 years upon its 1993 North American release.
  • Initial marketing emphasized a lack of adverse effects compared to other AEDs.
  • Severe adverse events (aplastic anemia, liver toxicity) led to significant safety concerns and market withdrawal risk.

Conclusions:

  • Felbamate's development and trial process were groundbreaking in epilepsy research.
  • Despite initial promise and unique trials, severe toxicity significantly impacted its availability.
  • Current primary indication is for refractory pediatric epilepsy, particularly Lennox-Gastaut syndrome.